AGEN
BEARISH
$3.99
Live
Agenus Inc. · NASDAQ
Target $12.33
(+209.1%)
$1.38
52W Range
$7.34
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 18, 2026
Market cap
$144.21M
P/E
N/A
ROE
N/A
Profit margin
-32.9%
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
AGEN's deterministic health scores are severely compromised: a Piotroski F-Score of 0/9 signals extreme financial distress, and the absence of an Altman Z-Score with negative profitability and liquidity ratios indicates high bankruptcy risk. Despite a 20.4% YoY revenue growth and recent EPS improvement, the company remains unprofitable with a -32.92% profit margin and negative ROA. The stock trades at a price/sales of 1.35, but with no intrinsic value or Graham Number, it lacks a fundamental floor. Analysts' target price of $12.33 is not supported by current fundamentals, suggesting overvaluation based on speculative growth expectations.
Key Strengths
20.4% year-over-year revenue growth indicates top-line expansion
Recent quarterly EPS growth of +68.1% Q/Q and +81.9% YoY shows improving earnings trajectory
Positive earnings surprise in Q1 2026 (+64.8%) suggests potential operational improvement
Strong analyst target price of $12.33 implies market optimism on future catalysts
Low market cap ($0.14B) offers potential for high volatility-driven upside
Key Risks
Piotroski F-Score of 0/9 indicates severe financial deterioration and operational instability
Negative ROA (-16.66%) and gross margin (0.08%) reflect deep profitability issues
Extremely weak liquidity: current ratio of 0.47 and quick ratio of 0.03 signal imminent cash flow stress
No free cash flow, operating cash flow, or debt/equity data suggests opaque financial health
Historical earnings surprises are highly volatile and often negative, with average surprise of -87.35% over last 4 quarters
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
22
Weak
20
55
25
10
0
AI Verdict
High Risk
Key drivers: Piotroski F-Score of 0/9, Negative profitability and liquidity, No meaningful valuation anchors, High volatility in earnings surprises
Confidence
90%
Value
20/100
Ref P/E, PEG, Graham Number
Positives
- Price/Sales of 1.35 is below sector average of 164.49
- Low market cap may offer speculative upside
Watchpoints
- No Graham Number or intrinsic value available
- Negative P/E and Price/Book ratios indicate no earnings or book value support
- Stock trades at a premium to any potential fair value due to growth speculation
Future
55/100
Ref Growth rates
Positives
- 20.4% YoY revenue growth
- Improving EPS trends with +81.9% YoY and +68.1% Q/Q growth
- Analyst target price of $12.33 reflects growth optimism
Watchpoints
- No forward P/E or PEG available
- Profitability remains deeply negative
- Growth not yet translating into sustainable earnings
Past
25/100
Ref Historical trends
Positives
- Some recent quarters show positive earnings surprises
- Historical EPS has shown cyclical improvement
Watchpoints
- Average earnings surprise of -87.35% over last 4 quarters
- Persistent losses with negative margins across all metrics
- High volatility in actual vs. estimated earnings
Health
10/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- No debt/equity data may suggest low leverage, but this is speculative
Watchpoints
- Piotroski F-Score of 0/9 indicates extreme financial distress
- Current ratio of 0.47 and quick ratio of 0.03 indicate severe liquidity risk
- No operating cash flow or free cash flow data
- Negative ROA and ROIC
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend strength of 0/100
- Company is not dividend-paying and has no history of distributions
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$3.99
Analyst Target
$12.33
Upside/Downside
+209.1%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AGEN and closest competitors.
Updated 2026-03-17
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AGEN
Agenus Inc.
Primary
|
-93.5% | -88.0% | +124.2% | -10.7% | +36.6% | +18.4% |
|
EMPG
Empro Group Inc.
Peer
|
+299.1% | +299.1% | +299.1% | -2.2% | 0.0% | 0.0% |
|
NYXH
Nyxoah SA
Peer
|
-85.9% | -65.9% | -43.6% | -44.6% | +7.1% | +11.4% |
|
APYX
Apyx Medical Corporation
Peer
|
-68.5% | +28.3% | +249.0% | +72.9% | -7.4% | +16.4% |
|
IPHA
Innate Pharma S.A.
Peer
|
-67.1% | -58.3% | -22.5% | -30.5% | -9.0% | +2.9% |
AGE
Agenus Inc.
Primary
5Y
-93.5%
3Y
-88.0%
1Y
+124.2%
6M
-10.7%
1M
+36.6%
1W
+18.4%
EMP
Empro Group Inc.
Peer
5Y
+299.1%
3Y
+299.1%
1Y
+299.1%
6M
-2.2%
1M
0.0%
1W
0.0%
NYX
Nyxoah SA
Peer
5Y
-85.9%
3Y
-65.9%
1Y
-43.6%
6M
-44.6%
1M
+7.1%
1W
+11.4%
APY
Apyx Medical Corporation
Peer
5Y
-68.5%
3Y
+28.3%
1Y
+249.0%
6M
+72.9%
1M
-7.4%
1W
+16.4%
IPH
Innate Pharma S.A.
Peer
5Y
-67.1%
3Y
-58.3%
1Y
-22.5%
6M
-30.5%
1M
-9.0%
1W
+2.9%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-1.73
PEG Ratio
N/A
P/B Ratio
-0.48
P/S Ratio
1.35
EV/Revenue
1.38
EV/EBITDA
-2.94
Market Cap
$144.21M
Profitability
Profit margins and return metrics
Profit Margin
-32.92%
Operating Margin
-16.08%
Gross Margin
0.08%
ROE
N/A
ROA
-16.66%
Growth
Revenue and earnings growth rates
Revenue Growth
+20.4%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
0.47
Weak
Quick Ratio
0.03
Poor
Cash/Share
$0.1
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q3 2025
Revenue
$0.0B
Gross Margin
19.8%
Op. Margin
-16.1%
Net Margin
211.4%
Total Assets
$0.2B
Liabilities
$0.5B
Equity
$-0.3B
Debt/Equity
-1.88x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-11
$N/A
2026-03-16
$-0.37
+64.8% surprise
2025-11-10
$-1.16
-152.9% surprise
2025-08-11
$-1.0
-173.9% surprise
Healthcare Sector Comparison
Comparing AGEN against 393 companies in the Healthcare sector
(24 bullish, 129 neutral, 240 bearish)
Profit Margin
-32.92%
This Stock
vs
-12.47%
Sector Avg
+164.0%
(Superior)
Revenue Growth
20.4%
This Stock
vs
124.21%
Sector Avg
-83.6%
(Slower)
Current Ratio
0.47
This Stock
vs
4.56
Sector Avg
-89.8%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AGEN
Agenus Inc.
|
BEARISH | $144.21M | - | -% | -32.9% | $3.99 | |
|
EMPG
Empro Group Inc.
|
NEUTRAL | $143.05M | 192.89 | 66.3% | 13.7% | $17.36 | Compare |
|
NYXH
Nyxoah SA
|
BEARISH | $147.36M | - | -111.0% | -% | $3.38 | Compare |
|
APYX
Apyx Medical Corporation
|
BULLISH | $148.94M | - | -76.1% | -21.2% | $3.63 | Compare |
|
IPHA
Innate Pharma S.A.
|
BEARISH | $132.24M | - | -% | -% | $1.41 | Compare |
AGEN
Agenus Inc.
BEARISH
Mkt Cap
$144M
P/E
-
ROE
-%
Price
$3.99
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-06 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 4,994 | $14,782 |
| 2026-02-20 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 4,829 | $14,777 |
| 2026-02-06 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 5,027 | $14,779 |
| 2026-01-23 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 4,562 | $14,781 |
| 2026-01-09 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 3,780 | $14,780 |
| 2026-01-02 | HARRISON THOMAS L | Director | Stock Award | 7,691 | $24,842 |
| 2025-12-26 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 4,942 | $16,358 |
| 2025-12-12 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 4,316 | $16,358 |
| 2025-11-28 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 3,587 | $16,357 |
| 2025-11-14 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 3,769 | $16,357 |
| 2025-10-31 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 4,120 | $16,356 |
| 2025-10-17 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 4,216 | $16,358 |
| 2025-10-03 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 3,951 | $16,357 |
| 2025-10-01 | HARRISON THOMAS L | Director | Stock Award | 5,780 | $22,542 |
ARMEN GARO H.
Chief Executive Officer
2026-03-06
4,994 shares
·
$14,782
ARMEN GARO H.
Chief Executive Officer
2026-02-20
4,829 shares
·
$14,777
ARMEN GARO H.
Chief Executive Officer
2026-02-06
5,027 shares
·
$14,779
ARMEN GARO H.
Chief Executive Officer
2026-01-23
4,562 shares
·
$14,781
ARMEN GARO H.
Chief Executive Officer
2026-01-09
3,780 shares
·
$14,780
HARRISON THOMAS L
Director
2026-01-02
7,691 shares
·
$24,842
ARMEN GARO H.
Chief Executive Officer
2025-12-26
4,942 shares
·
$16,358
ARMEN GARO H.
Chief Executive Officer
2025-12-12
4,316 shares
·
$16,358
ARMEN GARO H.
Chief Executive Officer
2025-11-28
3,587 shares
·
$16,357
ARMEN GARO H.
Chief Executive Officer
2025-11-14
3,769 shares
·
$16,357
ARMEN GARO H.
Chief Executive Officer
2025-10-31
4,120 shares
·
$16,356
ARMEN GARO H.
Chief Executive Officer
2025-10-17
4,216 shares
·
$16,358
ARMEN GARO H.
Chief Executive Officer
2025-10-03
3,951 shares
·
$16,357
HARRISON THOMAS L
Director
2025-10-01
5,780 shares
·
$22,542
Insider transactions can signal confidence or concerns about company prospects
Past News Coverage
Recent headlines mentioning AGEN from our newsroom.
Newest → oldest
No matching news yet.